Ep147: Reid Huber on Investing in the Future of Medicine

Episode Summary

Executive Summary: Reid Huber traces his path from a small-town Midwestern upbringing and early genetics training to a biotech career spanning DuPont Merck, Insight, and Third Rock Ventures. He argues biotech is in a golden age of engineering-driven drug discovery, but warns policy and financing headwinds like the IRA could distort innovation incentives. He emphasizes patient-first company building, syndication, and mentoring new talent.

Main Topics: Early life and scientific curiosity (Priority: 5/5): Huber describes growing up in Fairview Heights, Illinois, in a middle-class family with strong influences from an engineer father and nurse mother, plus formative teachers and an early fascination with astronomy and abstract science. College baseball and the pivot to genetics (Priority: 5/5): At Murray State, Huber pursued baseball on scholarship while studying aquatic biology, then discovered human genetics through a faculty seminar, which redirected his scientific path toward DNA sequencing and disease genetics. Genome project era and graduate training at Wash U (Priority: 5/5): At Washington University in the 1990s, he worked on X-chromosome mapping and cloning during the Human Genome Project, gaining first-hand experience with positional cloning, rare disease genetics, and protein function. Transition from academia to biotech industry (Priority: 5/5): Huber moved from postdoctoral work into DuPont Merck and then Insight, learning small-molecule drug discovery, medicinal chemistry, PK/PD, and what makes a high-quality drug program likely to succeed. Insight’s JAK2 success and long R&D run (Priority: 5/5): At Insight, he helped build a genomics-informed drug discovery engine that led to ruxolitinib and multiple approvals, reinforcing his belief that strong biology plus disciplined chemistry can produce rapid patient impact. Third Rock Venture model and company creation (Priority: 4/5): At Third Rock, Huber explains the firm’s patient-first, highly collaborative culture and its evolution toward more mature financings, broader syndication, and company launches that are better positioned to reach clinical value milestones. Policy, financing, and the future of biotech (Priority: 5/5): He critiques the Inflation Reduction Act’s effects on small molecules and orphan-disease strategies, while remaining optimistic that biotech is in a golden age driven by converging modalities, deep learning, and engineering principles.

Key Arguments: Human genetics became actionable for drug discovery as sequencing, mapping, and later engineering tools matured; Huber’s career reflects that transition from gene discovery to medicines. Industry training can be as scientifically rigorous as academia, and in many cases better aligned with turning discoveries into patient benefit. A strong drug discovery program depends on drug-like properties, PK/PD, dose predictability, and chemistry/biology integration—not just novel targets. Insight’s JAK program shows how a genomic clue can lead to an approved medicine quickly when the biology is compelling and the team is disciplined. Third Rock differentiates itself by measuring success through approved medicines and patient impact, not just company creation or paper value. Venture-backed biotech should stay bold in innovation but use tools like later-stage maturation and heavy syndication to reduce execution risk. The IRA may unintentionally discourage small-molecule investment and orphan-first development strategies that have historically enabled major therapeutic advances. Biotech is entering a golden age because medicines are now increasingly engineered, and computation/deep learning are accelerating hypothesis testing and target selection. Young people should be brought into biotech through exposure, mentorship, and role models because curiosity and patient impact are powerful motivators once they see the field firsthand.

Data Points: Third Rock portfolio companies: 62 - Total companies created since the firm’s founding in 2007 Approved products from Third Rock companies: 20 - Medicines that have made it through clinical trials and onto the market Third Rock fund size: $1.1 billion - The firm’s sixth fund mentioned by the host Huber tenure at Insight: 17 years - Time spent at Insight before joining Third Rock Ventures Age of ruxolitinib pathway to approval: 6 years - From JAK2 mutation discovery in 2005 to approval in 2011 Phase 3 timing for ruxolitinib: 2009 - Trial phase progression after first patient dosing in myelofibrosis First patient dosing with ruxolitinib: 2007 - Early clinical proof of concept for myelofibrosis Third Rock launches since Huber joined: 14 or 15 series A launches - He says these have been heavily syndicated Small-molecule / large-molecule price control timing: 13 and 13 vs. 9 and 9 - Huber references possible legislative fixes or further tightening under the IRA Oncology copay abandonment threshold: More than $2,000 - Patients with high out-of-pocket costs are far more likely to abandon therapy Oncology medicine abandonment rate increase: Almost 5x - High copays greatly increase discontinuation rates Biotech internships goal: 1,000 internships by 2027 - Life Science Cares initiative supported by Huber and Third Rock Third Rock company creation focus in oncology: Just over half - He says more than half of the firm’s startups are in oncology

Pivotal Quotes: "“We are in a very special time of innovation and convergence in science.”" — Luke Timmerman: Host’s reflection near the end on the pace of modern biotech progress and clinical breakthroughs "“I think of the same reason I entered into it. It's curiosity and a wonder of what's yet to be discovered and a belief that you can impact a patient by that discovery.”" — Reid Huber: Explaining why biotech is compelling for young people entering the field "“We don't have drug discovery programs per se. We have companies in our portfolio or in our pipeline, but the North star is exactly the same.”" — Reid Huber: Describing Third Rock’s patient-impact-driven venture model

Implications: Biotech’s future looks strong if it keeps pairing bold science with patient-first execution, but policy must avoid suppressing small-molecule and orphan-disease innovation. Talent development, syndication, and engineering-driven R&D will shape the next decade.